Scientific Online Resource System

Varna Medical Forum

Does modern chemical analysis allow the identification of passive cannabis smokers?

Stanila Stoeva

Abstract

Cannabis continues to be the most widely used drug worldwide. This increases the risk of positive drug tests in individuals with a secondary exposure. For this reason, the aim of the present work was to clarify the possibilities of modern toxicochemical analysis to distinguish the biological samples of passive smokers of cannabis.

The algorithm by which drug use is monitored today includes the sequential implementation of screening and evidentiary analytical methods. Through the former, possible drug users are filtered, and through the latter, the reliability of the obtained results is categorically confirmed.

Due to its kinetic characteristics, the main psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), is sometimes replaced as a target analyte by one of its metabolites. In urine, which is the most frequently studied type of biological matrix, it is practice to determine the amount of non-pharmacologically active 11-nor-9-carboxy-Δ9-tetrahydrocanbinol. It has been established that in passive smokers its concentrations do not exceed 50 ng/mL in drug screening and 15 ng/mL in confirmatory analysis. Alternatively, THC and/or its metabolites can be tested in blood, hair, saliva, and others.

The analytical tools of the XXI century allow the identification of individuals exposed to the psychoactive agent THC in a passive way. This does not, however, negate the personal responsibility of each individual to avoid playing the role of a passive smoker.


Keywords

cannabis, marijuana, passive smoking, toxicological analysis

Full Text


References

Асоциация „Солидарност“. Национална информационна линия за наркотиците, алкохола и хазарта. Какво са хашиш и марихуана? https://www.drugsinfo-bg.org/azbuka-na-narkoticite/kanabis/kakvo-sa-hashish-i-marihuana/ (Accessed Aug 24, 2023).

Атанасов В. Експертиза на употребата на алкохол и наркотични вещества от участниците в пътното движение. В: Атанасов В, ред. Съдебна токсикология. Принципи и практика. София: Военномедицинска Академия; 2020. стр. 79-144.

Атанасов В. Токсикохимичен анализ за целите на спешната медицина и клиничната токсикология. В: Атанасов В, ред. Съдебна токсикология. Принципи и практика. София: Военномедицинска Академия; 2020. стр. 11-78.

Anderson LA, Can a Drug Test Lead to a False Positive? 2021 https://www.drugs.com/article/false-positive-drug-tests.html (Accessed Aug 24, 2023).

Antunes M, Barroso M, Gallardo E. Analysis of Cannabinoids in Biological Specimens: An Update. Int J Environ Res Public Health. 2023;20(3):2312.

Barco S, Fucile C, Manfredini L, De Grandis E, Gherzi M, Martelli A, Tripodi G, Mattioli F, Cangemi G. A UHPLC-MS/MS method for the quantification of Δ9-tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis. Bioanalysis. 2018;10(24):2003-2014.

Benowitz NL. Marijuana. In: Olson K, Anderson I, Benowitz N, Blanc P, Clark R, Kearney T, Kim-Katz S, Wu A, editors. Poisoning and Drug Overdose, Seventh Edition. New York: McGrow Hill; 2017. pp 304-306.

Berthet A, De Cesare M, Favrat B, Sporkert F, Augsburger M, Thomas A, Giroud C. A systematic review of passive exposure to cannabis. Forensic Sci Int. 2016;269:97-112.

Busardò FP, Pérez-Acevedo AP, Pacifici R, Mannocchi G, Gottardi M, Papaseit E, Pérez-Mañá C, Martin S, Poyatos L, Pichini S, Farré M. Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. Pharmaceuticals (Basel). 2021;14(1):59.

Busuttil A, Obafunwa JO, Bulgin S. Passive inhalation of cannabis smoke: a novel defence strategy? J Clin Forensic Med. 1996;3(2):99-104.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R. Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. J Anal Toxicol. 2015;39(1):1-12.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R. Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects. J Anal Toxicol. 2015;39(7):497-509.

Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther. 1986;40(3):247-256.

Fabritius M, Favrat B, Chtioui H, Battistella G, Annoni JM, Appenzeller M, Dao K, Fornari E, Lauer E, Mall JF, Maeder P, Mangin P, Staub C, Giroud C. THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers? Drug Test Anal. 2014;6(1-2):155-163.

Fraser AD, Worth D. Urinary Excretion Profiles of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol: A Δ9-THCCOOH to Creatinine Ratio Study. JAT. 1999;23(6):531–534.

Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, Godlewska B, Cornish R, Williams J, Di Simplicio M, Igoumenou A, Brenneisen R, Tunbridge EM, Harrison PJ, Harmer CJ, Cowen P, Morrison PD. How Cannabis Causes Paranoia: Using the Intravenous Administration of ∆ 9 -Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia. Schizophrenia Bulletin. 2015;41(2):391-399.

Fu S. Adulterants in Urine Drug Testing. Adv Clin Chem. 2016; 76: 123-163.

Goodwin RS, Darwin WD, Chiang CN, Shih M, Li SH, Huestis MA. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32(8):562-569.

Goullé JP, Lacroix C. Mise en évidence des cannabinoïdes: quel milieu biologique? [Which biological matrix for cannabis testing?]. Ann Pharm Fr. 2006;64(3):181-191.

Graves BM, Johnson TJ, Nishida RT, Dias RP, Savareear B, Harynuk JJ, Kazemimanesh M, Olfert JS, Boies AM. Comprehensive characterization of mainstream marijuana and tobacco smoke. Sci Rep. 2020;10:7160.

Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Bio divers. 2007;4:1744–1769.

Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, Vandrey R. Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. Drug Alcohol Depend. 2015;151:194-202.

Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804.

Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V. Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. J Mass Spectrom. 2009;44(10):1423-1433.

Lapoint JM. Cannabinoids. In: Nelson L, Hoffman R, Howland M, Lewin N, Smith SW, Goldfrank L, editors. Goldfrank's Toxicologic Emergencies, Eleventh Edition. New York: McGrow Hill; 2019. pp. 1111-1123.

Logan BK, Osselton MD. Driving Under the Influence of Drugs. In: Moffat AC, Osselton MS, Widdop B, editors. Clarke's Analysis of Drugs and Poisons, 4th Edition. London: Pharmaceutical Press; 2011. pp. 115-126.

Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens. Mayo Clin Proc. 2017;92(5):774-796.

Moffat AC. Monitoring urine for inhaled cannabinoids. Arch Toxicol. 1986;59:103–110.

Moore C. Response toIs THCCOOH a useful determinant for passive inhalation in oral fluid THC testing? J Anal Toxicol. 2012;36(5):358.

Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006;28(2):155-163.

Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, Waga J, Kurtz L, Bronsgeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol. 2005;29(7):607-615.

Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol. 2004;28(7):546-552.

Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017; 55:1555-1563.

Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Cook CE. The pharmacologic effects of daily marijuana smoking in humans. Pharmacol Biochem Behav. 1991;40:691-694.

Reisfield G, Goldberger B, Bertholf R. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 2009;1(5): 937-952.

Roth SH, Williams PJ. The non-specific membrane binding properties of delta9-tetrahydrocannabinol and the effects of various solubilizers. J Pharm Pharmacol. 1979;31(4):224-230.

Scheidweiler KB, Desrosiers NA, Huestis MA. Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta. 2012;413(23-24):1839-1847.

Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149-156.

Smith MP, Bluth MH. Common Interferences in Drug Testing. Clin Lab Med. 2016;36(4):663-671.

UNODC, World Drug Report 2022; Booklet 3 - Drug market trends. Cannabis. Opioids. https://www.unodc.org/res/wdr2022/MS/WDR22_Booklet_3.pdf (Accessed Aug 24, 2023).

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473.

Wiencek JR, Colby JM, Nichols JH. Rapid Assessment of Drugs of Abuse. Adv Clin Chem. 2017;80:193-225.




DOI: http://dx.doi.org/10.14748/vmf.v12i2.9192

Refbacks

Font Size


|